Clinical trials: Cancer, Bladder
Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types.
- Conditions
- Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC), Mesothelioma, Pheochromocytoma/Paraganglioma (PPGL)
- Trial name
- NCT06503146
- Testing
- [18F]FAPI-74, [18F]FDG
- Where
- United States
- Volunteers
- 320 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy
The purpose of this clinical trial is to determine if prostate-capsule-sparing cystectomy improves functional outcomes without comprising oncologic outcomes in male patients receiving a radical cystectomy.
- Trial name
- NCT05792722
- Testing
- Prostate capsule-sparing radical cystectomy, Nerve sparing radical cystectomy
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Johns Hopkins University
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT03245736
- Testing
- Tisotumab Vedotin
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 5 people
- Sponsor
- Seagen Inc.
Bladder Cancer
En-bloc vs Conventional Resection of Primary Bladder Tumor
Based on current evidence, we hypothesize that eTURB represents an improvement in the surgical management of NMIBC. The resection is more precise and complete compared to cTURB.
- Trial name
- eBLOC (NCT03718754)
- Testing
- En-Bloc TURB, Conventional TURB
- Where
- Austria
- Volunteers
- 384 people
- Sponsor
- David D'Andrea
Bladder Cancer, Head and Neck Squamous Cell Carcinoma
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer.
- Conditions
- Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland, Lung Cancer
- Trial name
- VISTA (NCT03740256)
- Testing
- CAdVEC
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Baylor College of Medicine
Malignant Neoplasms of Urinary Tract, Bladder Cancer
Investigation of Sugammadex in Outpatient Urological Procedures
The goal of this clinical research study is to determine whether using sugammadex, given with a standard muscle relaxation drug during bladder surgeries, improves anesthesia conditions and recovery time.
- Trial name
- NCT03138967
- Testing
- Rocuronium, Sugammadex, Neostigmine
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor, Metastatic Bladder Cancer
Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
The purpose of this study is to determine the maximum tolerated dose of RX-3117 in subjects with advanced or metastatic solid tumors (Phase 1).
- Trial name
- NCT02030067
- Testing
- RX-3117
- Where
- 12 sites in United States
- Volunteers
- 127 people
- Sponsor
- Processa Pharmaceuticals
Bladder Cancer
Evaluation of the PhageTech Virus BioResistor
To evaluate the effectiveness of the PhageTech Virus BioResistor to detect bladder cancer biomarkers.
- Trial name
- NCT04756284
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- PhageTech, Inc.
Locally Advanced Bladder Cancer
Adjuvant Post-radical Cystectomy Treatment for Bladder Cancer
Radical Cystectomy is still the standard treatment in muscle-invasive Bladder cancer. Local recurrence is still the major cause of failure together with distant metastasis.
- Trial name
- NCT01734798
- Testing
- Radiation, gemcitabine and cisplatin, Radiotherapy and Drug
- Where
- Egypt
- Volunteers
- 198 people
- Sponsor
- Cairo University
Bladder Cancer
Information Needs and Supportive Rehabilitation Over Time in Patients Undergoing Cystectomy in Bladder Cancer
Bladder cancer is one of the diseases that can affect the urinary tract. Globally, it is the tenth most common cancer, with an incidence rate of 9.5 per 100,000 persons per year for men and 2.4 for women.
- Trial name
- CaRe (NCT07180121)
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- Linkoeping University
Bladder Cancer
RARC vs LRC in A Multicenter Cohort Study
A multicenter, retrospective research was conducted. Patients who underwent robot-assisted radical cystectomy and laparoscopic radical cystectomy in 10 large medical centers in China were enrolled, comparing the oncologic…
- Trial name
- NCT05885204
- Testing
- Robot-assisted radical cystectomy, Conventional laparoscopic radical cystectomy
- Volunteers
- 3,815 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Bladder Cancer
Study of Tumour Focused Radiotherapy for Bladder Cancer
Bladder cancer is the seventh most common cancer in the UK, with 10,399 new cases diagnosed in 2011. In a quarter of these cases the cancer has infiltrated the muscular wall of the bladder (muscle invasive) and is life…
- Trial name
- RAIDER (NCT02447549)
- Testing
- WBRT, SART, DART
- Where
- 49 sites in Australia, New Zealand and 1 more
- Volunteers
- 345 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Bone Cancer, Brain Cancer
Enhanced Assistance During Radiotherapy for Unmet Essential Needs
This is a prospective single-arm study of an enhanced assistance intervention for patients with unmet essential needs undergoing >10 fractions of radiotherapy comparing delay-free completion of radiotherapy in study participants…
- Conditions
- Bone Cancer, Brain Cancer, Colorectal Cancer, Esophagus Cancer
- Trial name
- EARN (NCT06582849)
- Testing
- Standard assistance, Enhanced assistance
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Washington University School of Medicine
Advanced/Metastatic Solid Tumors, Bladder Cancer
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas.
- Conditions
- Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
- Trial name
- NCT07090499
- Testing
- PF-08046876, Pembrolizumab, Cisplatin
- Where
- 31 sites in United States, Canada and 4 more
- Volunteers
- 540 people
- Sponsor
- Pfizer
NMIBC
A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
A Phase I-II Study of Novel Oncolytic Virus VG161 via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (VG-INFUSE Trial) Background: The treatment of recurrent/refractory non-muscle-invasive…
- Trial name
- VG-INFUSE Tria (NCT07505615)
- Testing
- VG161 via Intravesical Instillation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ding-Wei Ye
Hematuria, Urinary Bladder Neoplasms
Peri-operative Aspirin Continuation Versus Discontinuation
This study evaluates the continuation (non-discontinuation) of Aspirin during TURBT. Half of participants will continue their usual low-dose Aspirin regimen during TURBT and throughout the perioperative period, while the other…
- Trial name
- NCT02350543
- Testing
- Aspirin
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Rabin Medical Center
Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
This phase III trial compares the effect of adding cabozantinib to avelumab versus avelumab alone in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body…
- Conditions
- Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Advanced Urethral Urothelial Carcinoma
- Trial name
- NCT05092958
- Testing
- Avelumab, Biospecimen Collection, Bone Scan
- Where
- 275 sites in United States, Canada
- Volunteers
- 654 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
Markers of Response to Intravesical Bladder Cancer Therapy
The goal of this laboratory research study is to see if researchers can predict whose cancer will stay in remission and whose will return in patients receiving treatment for bladder cancer.
- Trial name
- NCT01007058
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Neoplasms
Intravesical Chemotherapy Treatment of Superficial Bladder Cancer
This is a phase II study where chemotherapy (gemcitabine) is given into the urinary bladder.
- Trial name
- NCT00491114
- Testing
- Gemcitabine
- Where
- 7 sites in Italy
- Volunteers
- 8 people
- Sponsor
- Eli Lilly and Company
Bladder Cancer
Optimal Adjuvant Intravesical Therapy for Intermediate Risk Non Muscle Invasive Bladder Cancer: A Randomized Controlled Trial
The objective of this prospective, single-center randomized controlled trial is to identify the optimal adjuvant intravesical therapy in patients with intermediate risk (IR) non muscle invasive bladder cancer by comparing two…
- Trial name
- NCT05146635
- Testing
- Intravesical Bcg, Intravesical chemotherapy (epirubicin)
- Where
- Egypt
- Volunteers
- 110 people
- Sponsor
- Mansoura University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.